REG - Oxford BioDynamics - Publication of FY22 Annual Report

Oxford BiodynamicsAnnouncement

03/03/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230303:nRSC9037Ra&default-theme=true

RNS Number : 9037R  Oxford BioDynamics PLC  03 March 2023

3 March
2023

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Publication of 2022 Annual Report

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing
precision medicine tests for immune health based on the EpiSwitch® 3D
genomics platform, today announces that copies of its annual report and
accounts for the year ended 30 September 2022 (incorporating the Notice of
Annual General Meeting) ("Annual Report") have been posted to shareholders. An
electronic copy of the Annual Report will be available on its website at
www.oxfordbiodynamics.com/investors/financial-results.

As stated in the recent Full Year results announcement, the Company's Annual
General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford
Business Park South, Oxford, OX4 2WB, on 30 March 2023 at 12.00pm.

-Ends-

 

For further details please contact:

 

 Oxford BioDynamics Plc              +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital                       +44 (0)20 7408 4090

 Nominated Adviser and Broker

 Stephane Auton

 John More

 Instinctif Partners                 Tel: +44 (0)20 7457 2020
 Melanie Toyne-Sewell / Rozi Morris  OxfordBioDynamics@instinctif.com

 

Notes for Editors

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (http://www.mycirt.com/) (Checkpoint
Inhibitor Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in February
2022.

In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch (https://covidseveritytest.com/) ® (https://covidseveritytest.com/)
(https://covidseveritytest.com/) CST (https://covidseveritytest.com/) (Covid
Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit (http://store.oxfordbiodynamics.com/) .

The Company has developed a proprietary 3D genomic biomarker platform,
EpiSwitch®, which can build molecular diagnostic classifiers for prediction
of response to therapy, patient prognosis, disease diagnosis and subtyping,
and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg, MD, USA and a
reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website,
www.oxfordbiodynamics.com (https://www.oxfordbiodynamics.com/) , or follow on
Twitter (https://twitter.com/OxBioDynamics) or LinkedIn
(https://www.linkedin.com/company/oxford-biodynamics/) .

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 10,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcome, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSUOUNROWUORAR